RE: Performance Issues22 Feb 2022 10:44
Vifor numbers are just great.
JTIT, seems like you did some research there.
If I look at Injectafer (how the Ferinject is know is USA), that seems to be an IV product.
If so, maybe it's not really a direct competition since Accrufer is meant to be a before-IV solution?
Recall that there are like 11m prescriptions per year in the US, of which something around 90% relate to oral iron therapies, and the rest has to be IV.
In case the above is correct, isn't Accrufer more of a complementary product to Injectafer, as opposed to a competitor?